In metabolic research and endocrinology, mono-agonists (such as GLP-1 analogues) and dual-agonists (GLP-1/GIP) have yielded significant breakthroughs in glycemic control and body composition regulation. However, multi-target pharmacology has advanced further with the development of triple G-protein coupled receptor (GPCR) agonism.
At the forefront of this field is Retatrutide (LY3437943), a...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)